-
Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-based Live Biotherapeutic
in PRESS RELEASE 2022 onFerring Pharmaceuticals and Rebiotix, a Ferring Company, announced today the first presentation of interim data from a Phase 3 open-label study showing strong trends in efficacy and safety for investigational microbiota-based live biotherapeutic RBX2660…
0 -
Ferring announces ground-breaking and inclusive family building benefits package for all its employees globally
in PRESS RELEASE 2022 onFerring Pharmaceuticals and Rebiotix, a Ferring Company, announced today the first presentation of interim data from a Phase 3 open-label study showing strong trends in efficacy and safety for investigational microbiota-based live biotherapeutic RBX2660…
-
Ferring Announces New Collaboration for Development of Olamkicept
in PRESS RELEASE 2022 onFerring Pharmaceuticals and Rebiotix, a Ferring Company, announced today the first presentation of interim data from a Phase 3 open-label study showing strong trends in efficacy and safety for investigational microbiota-based live biotherapeutic RBX2660…
-
Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic
in PRESS RELEASE 2022 onFerring Pharmaceuticals and Rebiotix, a Ferring Company, announced today the first presentation of interim data from a Phase 3 open-label study showing strong trends in efficacy and safety for investigational microbiota-based live biotherapeutic RBX2660…
-
Panicked and overwhelmed: NEW study reveals the emotional and psychological impact of infertility
in PRESS RELEASE 2022 onFerring Pharmaceuticals and Rebiotix, a Ferring Company, announced today the first presentation of interim data from a Phase 3 open-label study showing strong trends in efficacy and safety for investigational microbiota-based live biotherapeutic RBX2660…
-
Gender, health and racial inequalities to be tackled in flagship Ferring grant programme
in PRESS RELEASE 2022 onFerring Pharmaceuticals and Rebiotix, a Ferring Company, announced today the first presentation of interim data from a Phase 3 open-label study showing strong trends in efficacy and safety for investigational microbiota-based live biotherapeutic RBX2660…
PRESS RELEASE 2022
PRESS RELEASE 2022